FindTrial
Sign In

A real-world study of Omalizumab in the treatment of chronic urticaria in China

A real-world study of Omalizumab in the treatment of chronic urticaria in China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056599
Enrollment
Unknown
Registered
2022-02-08
Start date
2018-10-01
Completion date
Unknown
Last updated
2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic urticaria

Interventions

Case series:None

Sponsors

Dermatology Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who met the diagnostic criteria for chronic spontaneous urticaria and/or chronic induced urticaria; 2. Patients who received standardized treatment according to CU guidelines but still had the following conditions: UAS7 >= 7 or DLQI >= 6; 3. Received at least 3 subcutaneous injections of omalizumab and had at least 3 follow-up records.

Exclusion criteria

Exclusion criteria: 1. Known allergy to omalizumab; 2. Pregnant or lactating patients.

Design outcomes

Primary

MeasureTime frame
7-day urticaria activity score;—

Secondary

MeasureTime frame
urticaria control test;urticaria life quality score;dermatology life quality index;—

Countries

China

Contacts

Public ContactYao Xu

Dermatology Hospital, Chinese Academy of Medical Sciences

dryao_xu@126.com+86 13512513536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026